LIFE - aTyr Pharma, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

aTyr Pharma, Inc.

3545 John Hopkins Court
Suite 250
San Diego, CA 92121
United States

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Sanjay S. ShuklaPres, CEO & Director483.58kN/A1972
Dr. Paul R. SchimmelFounder & Director40kN/A1941
Dr. David J. KingChief Scientific OfficerN/AN/A1959
Dr. John D. MendleinStrategic Advisor & Director703.66kN/A1960
Dr. Sanuj K. RavindranBus. Advisor565.22kN/A1972
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 and is headquartered in San Diego, California.

Corporate Governance

aTyr Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.